Sanofi announced the sale of INBRX-101 from Inhibrx Biosciences via a license and assignment agreement on August 14, 2025.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sanofi announced the sale of INBRX-101 from Inhibrx Biosciences via a license and assignment agreement on August 14, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sanofi (Japan)
company in Tokyo, Japan
Nothing else this week.
Coverage
Newest first; wire copies grouped- PR NewswireInhibrx Reports Second Quarter 2025 Financial Results SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results f